跳至主要内容
临床试验/NCT02409732
NCT02409732已完成4 期

Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis

Dartmouth-Hitchcock Medical Center1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2015年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
24
试验地点
1
主要终点
Number of Participants With a Change in Clearance From Baseline

研究概览

简要总结

To evaluate the safety and efficacy of PDT with blue light and topical Levulan in the treatment of actinic cheilitis.

详细描述

The study will consist of a screening visit, up to three scheduled treatments, and two scheduled office visits. There can be a three-day window period for each scheduled visit in order to accommodate the subject's schedule and unforeseen scheduling conflicts.

  1. Visit 1 (Screening): Subjects can be screened for the study up to two weeks before Visit 2 (Baseline). During screening, the study will be reviewed, written informed consent obtained, and eligibility confirmed. If applicable, the washout from prohibited medications or treatments will be determined at this visit.
  2. Visit 2 (Baseline): Following signed, written informed consent and confirmation of eligibility, all subjects will have their lips photographed. Medical history, dermatologic exam, urine pregnancy test (if applicable), review of concomitant medications, clinical evaluations, and tolerability assessments will be performed at this visit. Study medication application to clean skin will be followed by a 90 minute incubation period under occlusion. Subsequently, patients will be exposed to blue light therapy for 16 minutes and 40 seconds. Post-therapy assessments will be performed afterwards, as well as education on appropriate sun protection methods.
  3. Visits 3-4: Subjects will return every six weeks for up to two additional treatments. Treatment will be discontinued once the patient has achieved clinical clearance. Tolerability assessments, study medication application, blue light therapy, post-therapy assessments, and photographs will be performed.
  4. Visit 5-6 (End of Study): Subjects will return 12 and 24 weeks after the last treatment for clinical evaluations, tolerability assessments, and photographs.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Must be able to understand and voluntarily sign an informed consent form
  • Must be male or female ≥ 18 years of age at the time of consent
  • Must be able to adhere to the study visit schedule and other protocol requirements
  • Must have a diagnosis of actinic cheilitis by histopathological evaluation of biopsy specimen or clinical presentation

排除标准

  • Inability to provide voluntarily consent or mentally incompetent
  • Active herpes labialis lesions
  • Subjects with any condition which places the subject at unacceptable risk if he/she were to participate in the study, or confounds the ability to interpret data from the study
  • Subjects with any other skin condition that might affect the evaluation of the study disease
  • Pregnant or breastfeeding female subjects
  • Subjects who have used any investigational medication within one month prior to study entry
  • Subjects who have been previously exposed to PDT and/or topical Levulan therapy for the treatment of actinic cheilitis
  • Subjects who have used local therapy (e.g. cryotherapy) or topical treatment (e.g. 5% fluorouracil) within three months of study entry
  • Subjects who have used an oral photosensitizing drug (e.g. Declomycin) within six months of study entry
  • Subjects who are currently using photosensitizing agents (e.g. thiazides, tetracyclines, fluoroquinolones, phenothiazines, and sulfonamides) because of the risk of augmented photosensitivity
  • Subjects who are frequently exposed to ultraviolet radiation (e.g. lifeguards, construction workers, frequent sunbed users, etc.)
  • Subjects with a history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins, or photodermatosis
  • Subjects with a known hypersensitivity to Levulan
  • Subjects who are immunocompromised

研究组 & 干预措施

PDT

Experimental

PDT with aminolevulinic acid hydrochloride (HCl) and blue light to the affected area of the lips every six weeks for up to three treatments

干预措施: aminolevulinic acid hydrochloride (Drug)

PDT

Experimental

PDT with aminolevulinic acid hydrochloride (HCl) and blue light to the affected area of the lips every six weeks for up to three treatments

干预措施: Photodynamic therapy with blue light (Procedure)

结局指标

主要结局

Number of Participants With a Change in Clearance From Baseline

时间窗: Visit 2 (Baseline) to Visit 5 or 6 (Week 24 or 36)

Clearance will be estimated clinically as minimal (0%-25%), mild (26%-50%), moderate (51%-75%), good (76%-99%), or complete (100%). Results will also be evaluated by comparing photographs before and immediately after treatments, and 12 and 24 weeks after the last treatment.

次要结局

  • Average Change in Participant Reported Pain(Baseline to Week 36)
  • Average Change in Local Skin Reactions to Blue Light Treatment(Baseline to Week 36)
  • The Number of Participants Who Developed a Local Skin Reaction to Blue Light Treatment: Vesiculation/Pustulation, Erosion/Ulceration, Crusting and Hyperpigmentation(Baseline to Week 36)
  • Number of Participants With Adverse Events(Baseline to Week 36)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Michael S. Chapman

Staff Physician

Dartmouth-Hitchcock Medical Center

研究点 (1)

Loading locations...

相似试验

Photodynamic Therapy (PDT) With Levulan and Blue... | 临床试验